{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:44:49Z","timestamp":1790066689061,"version":"4.0.1"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T00:00:00Z","timestamp":1369094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Haemophagocytic lymphohistiocytosis (\n                    <jats:styled-content style=\"fixed-case\">HLH<\/jats:styled-content>\n                    ) is a life threatening complication of\n                    <jats:styled-content style=\"fixed-case\">E<\/jats:styled-content>\n                    pstein\u2013\n                    <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\n                    arr virus (\n                    <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\n                    ) infection. The anti\u2010\n                    <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>\n                    20 antibody rituximab depletes\n                    <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\n                    cells, leading to improved outcomes for patients with\n                    <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\n                    \u2010associated\n                    <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\n                    \u2010lymphoproliferative disorders. To gather data on the use of rituximab in\n                    <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">HLH<\/jats:styled-content>\n                    , we performed a retrospective investigation involving 42\n                    <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">HLH<\/jats:styled-content>\n                    patients who had received treatment with rituximab\u2010containing regimens. On average, patients received 3 rituximab infusions (range 1\u201310) at a median dose of 375\u00a0mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    . In all patients, rituximab was administered with other\n                    <jats:styled-content style=\"fixed-case\">HLH<\/jats:styled-content>\n                    \u2010directed medications, including steroids, etoposide and\/or ciclosporin. Rituximab\u2010containing regimens appeared well tolerated and improved clinical status in 43% of patients. Examination of laboratory data obtained prior to and within 2\u20134\u00a0weeks after the first rituximab dose revealed significant reductions in\n                    <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\n                    load (median load pre\u2010rituximab: 114\u00a0200\u00a0copies\/ml, median post\u2010rituximab: 225\u00a0copies\/ml,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00\u00b70001) and serum ferritin levels (median ferritin pre\u2010rituximab: 4260\u00a0\u03bcg\/l, median post\u2010rituximab: 1149\u00a0\u03bcg\/l,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00\u00b7001). Thus, when combined with conventional\n                    <jats:styled-content style=\"fixed-case\">HLH<\/jats:styled-content>\n                    \u2010directed therapies, rituximab improves symptoms, reduces viral load and diminishes inflammation. These data support the incorporation of rituximab into future prospective clinical trials for patients with\n                    <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">HLH<\/jats:styled-content>\n                    .\n                  <\/jats:p>","DOI":"10.1111\/bjh.12386","type":"journal-article","created":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T08:29:17Z","timestamp":1369124957000},"page":"376-382","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":228,"title":["Treatment of\n                    <scp>E<\/scp>\n                    pstein\n                    <scp>B<\/scp>\n                    arr virus\u2010induced haemophagocytic lymphohistiocytosis with rituximab\u2010containing chemo\u2010immunotherapeutic regimens"],"prefix":"10.1111","volume":"162","author":[{"given":"DeepakBabu","family":"Chellapandian","sequence":"first","affiliation":[{"name":"Department of Pediatrics Einstein Medical Center Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupali","family":"Das","sequence":"additional","affiliation":[{"name":"Division of Oncology The Children's Hospital of Philadelphia Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Zelley","sequence":"additional","affiliation":[{"name":"Division of Oncology The Children's Hospital of Philadelphia Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Wiener","sequence":"additional","affiliation":[{"name":"Division of Oncology The Children's Hospital of Philadelphia Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Management Core The Children's Hospital of Philadelphia Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[{"name":"Division of Oncology The Children's Hospital of Philadelphia Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim E.","family":"Nichols","sequence":"additional","affiliation":[{"name":"Division of Oncology The Children's Hospital of Philadelphia Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"EBV\u2010HLH Rituximab Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,5,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701411441"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21423"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22037"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-284935"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/2424"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI40732"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e328339018c"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00855-9"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(02)00117-8"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181f84a52"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-041610-134208"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116721"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2005.05.007"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22774"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324533"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct1114348"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-198823000-00003"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282541"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.23.13765"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-298372"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2003.tb02548.x"},{"key":"e_1_2_9_24_1","first-page":"672","article-title":"Assessment of immunochemotherapy and stem cell transplantation on EBV\u2010associated hemophagocytic lymphohistiocytosis in children: a systematic review and meta analysis","volume":"16","author":"Qin Q.","year":"2012","journal-title":"European Review for Medical and Pharmacological Sciences."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.02.047"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05257"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e32834ec9c1"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24039"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5446.1957"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190210176"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181f2caef"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(03)70004-3"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/2042-4280-3-1"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi076"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2009.09.005"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12386","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T20:01:36Z","timestamp":1696276896000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,21]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1111\/bjh.12386"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12386","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,21]]},"assertion":[{"value":"2013-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-03-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}